Parkinson's Patient Visiting Teitur Trophics
Today, we at Teitur Trophics had the privilege of welcoming a person living with Parkinson’s disease, who shared his personal story and experiences with our team. Not through data, publications, or clinical language, but through lived experience and in his own words. And it left a deep impression on all of us.
He spoke with honesty and courage about what it means to live with Parkinson’s everyday. Not only the visible motor symptoms, but also the invisible burdens: brain fog, mood changes, and gastrointestinal challenges that make daily life more unpredictable, more demanding, and more exhausting. His story was a powerful reminder that Parkinson’s is far more than a movement disorder, it touches every aspect of a person’s independence, identity, and quality of life.
One sentence in particular stayed with us: “When something has left me, it has left me forever.”.
Those words captured the progressive nature of the disease more powerfully than any slide or report ever could. He spoke to the reality of function loss, of certainty, of freedom, something that patients are forced to navigate over time.
He also shared the ongoing challenge of finding the right treatment balance: years of medication adjustments, the burden of side effects, and the difficulty of living with therapies that can sometimes feel as unpredictable as the disease itself. One point came through with great clarity: patients do not only need better treatments, they need treatments they can trust, with safety and predictability that allow them to live with greater confidence and dignity.
Hereflected all in one sentence: “It is all about buying time, pushing away the exit door.”
Heartbreaking to hear, and impossible to forget. For us, this was more than a conversation. It was a reminder of the urgency behind everything we do. At Teitur Trophics, our mission is not simply to develop new therapies. It is to help change what the future can look like for people living with Parkinson’s disease and for the families who stand beside them.
We are deeply grateful to our guest for sharing his journey so openly. His honesty, vulnerability, and strength moved us all and strengthened our resolve to continue advancing TT-P34 with the ambition of delivering a disease-modifying therapy for Parkinson’s disease.
Some days in biotech are about progress.
Others are about purpose.
Today was about both.